antibodies goat anti sparcl1 (R&D Systems)
Structured Review
![A Pedigree structure and segregation of a <t>SPARCL1</t> variant. *DNA available. WGS whole genome sequenced. SPARCL1 , NM_004684: c.334G > A; p.(Glu112Lys), +/− heterozygous variant identified, +/+ wild type on both alleles, verified by PCR amplification and Sanger sequencing. B Sanger sequencing chromatogram of SPARCL1 exon 4 in affected individual III:8 demonstrating a heterozygous c.334G > A. C The functional motifs are as follows: signal peptide; FOLN (follistatin/osteonectin-like EGF domain); Kazal 1 (Kazal-type serine protease inhibitor domain); SPARC Ca bdg (secreted protein acidic and rich in cysteine Ca binding region). The disordered regions, parts of the protein lacking definition, are represented by light grey shading. Low-complexity regions are represented in blue shading. p.(Glu112Lys) is located in a disordered region of the protein. Domains are derived from data in Pfam. D Conservation of protein sequence across 14 species. E RNA-seq transcript expression of SPARCL1 in the different layers of the cornea. BLC basal limbal crypts, SLC superficial limbal crypts. Data were curated from bulk RNA-seq and presented as transcripts per million (TPM) [ , ].](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7396/pmc11607396/pmc11607396__41431_2024_1687_Fig1_HTML.jpg)
Antibodies Goat Anti Sparcl1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies goat anti sparcl1/product/R&D Systems
Average 94 stars, based on 33 article reviews
Images
1) Product Images from "Autosomal dominant stromal corneal dystrophy associated with a SPARCL1 missense variant"
Article Title: Autosomal dominant stromal corneal dystrophy associated with a SPARCL1 missense variant
Journal: European Journal of Human Genetics
doi: 10.1038/s41431-024-01687-8
Figure Legend Snippet: A Pedigree structure and segregation of a SPARCL1 variant. *DNA available. WGS whole genome sequenced. SPARCL1 , NM_004684: c.334G > A; p.(Glu112Lys), +/− heterozygous variant identified, +/+ wild type on both alleles, verified by PCR amplification and Sanger sequencing. B Sanger sequencing chromatogram of SPARCL1 exon 4 in affected individual III:8 demonstrating a heterozygous c.334G > A. C The functional motifs are as follows: signal peptide; FOLN (follistatin/osteonectin-like EGF domain); Kazal 1 (Kazal-type serine protease inhibitor domain); SPARC Ca bdg (secreted protein acidic and rich in cysteine Ca binding region). The disordered regions, parts of the protein lacking definition, are represented by light grey shading. Low-complexity regions are represented in blue shading. p.(Glu112Lys) is located in a disordered region of the protein. Domains are derived from data in Pfam. D Conservation of protein sequence across 14 species. E RNA-seq transcript expression of SPARCL1 in the different layers of the cornea. BLC basal limbal crypts, SLC superficial limbal crypts. Data were curated from bulk RNA-seq and presented as transcripts per million (TPM) [ , ].
Techniques Used: Variant Assay, Amplification, Sequencing, Functional Assay, Protease Inhibitor, Binding Assay, Derivative Assay, RNA Sequencing Assay, Expressing
Figure Legend Snippet: A , E Merge of DAPI and SPARCL1 channels show an upregulation of SPARCL1 in the epithelial layer of the affected tissue. B , F Merge DAPI and decorin channels. The downregulation of decorin is evident in the stroma of the affected tissue. C , G Merge of all three channels. Scale bars correspond to 50 μm. D , H Magnification box of ( C ) and ( G ), respectively, scale bars correspond to 5 μm, perinuclear co-localisation of SPARCL1 and decorin is observed in affected tissue.
Techniques Used:
